Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

68 results about "Blepharitis" patented technology

An inflammation of the eyelids.

Isoxazoline parasiticide formulations

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Bifidobacterium animalis for relieving eye allergy and application thereof

PendingCN121592551ASenses disorderBacteriaDiseaseSwollen eyelid
The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.
Owner:ZHONGKE WISBIOM(BEIJING)BIOTECHNOLOGY CO LTD

Formulations and methods for treating conditions of the eye

The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.
Owner:SIGHT SCIENCES INC

Method of treatment

A new method of treating a skin disease or condition in a human subject caused by a parasite, particularly Demodex mite infestations that result in demodicosis, with moxidectin. The demodicosis is typically Demodex blepharitis.
Owner:ATTICUS MEDICAL PTY LTD

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Treatment of ocular disease

ActiveUS12673045B2DiseasePatient acceptance
The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.
Owner:PREMARK PHARMA GMBH

Methods for treating ocular Demodex using spinosad formulations

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

External traditional Chinese medicine composition and preparation for treating demodex blepharitis

The invention belongs to the field of traditional Chinese medicine compositions, and relates to an external traditional Chinese medicine composition and preparation for treating demodex blepharitis, the traditional Chinese medicine composition comprises the following raw materials by weight: 3-10 parts of coptis chinensis, 3-10 parts of sophora flavescens, and 7.5-10 parts of saposhnicovia divaricata. According to the formula, coptis chinensis and radix sophorae flavescentis are used as monarch drugs for clearing away heat and drying dampness and killing parasites to relieve itching, and the pathogenesis core of demodex infection and damp-heat interweaving is adopted; divaricate saposhnikovia root is used as a ministerial drug to dispel wind and eliminate dampness, eliminate swelling and relieve itching and help the monarch drug to relieve wind pathogen symptoms such as red, swollen, itching and pain of eyelids. In addition, the radix saposhnikoviae is slightly warm in nature and flavor, has the function of adjuvant drugs in the formula, and moderately restricts the bitter and cold nature of the coptis chinensis and the radix sophorae flavescentis; the traditional Chinese medicine composition is an external preparation, no conductant drug is independently arranged in the whole formula, and the formula is further simplified on the premise that the curative effect is guaranteed. The whole formula directly aims at the pathological core of vermiform mite infection and inflammatory response through triple action mechanisms of clearing away heat and toxic materials, dispelling wind and eliminating dampness and killing parasites to relieve itching. The total effective rate of the traditional Chinese medicine composition for demodex blepharitis reaches 94%, and the traditional Chinese medicine composition has the advantages of stable curative effect, high total effective rate, low recurrence rate, small side effect and the like.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Processes and compositions with antibacterial properties for the treatment of demodex blepharitis

Provided herein are compositions for the prevention and treatment of demodex blepharitis in a subject and processes of treatment or prevention of demodex blepharitis. The compositions may include at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a or 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof, and melatonin, wherein an aggregate concentration of the avermectin compound is optionally less than 1 wt %. Further devices are provided that include wipe including a woven or non-woven membrane and a treatment composition, the treatment composition including melatonin, one or more anti-microbial compounds, and optionally one or more pharmaceutically acceptable excipients and processes of treatment or prevention of demodex blepharitis in a subject using the wipe, alone or optionally further with the composition as provided herein.
Owner:TOYOS ROLANDO

Dry eye treatment

Disclosed are ophthalmic compositions for removing biofilms from the eye and for treating inflammation, blepharitis and dry eye of the eye, the ophthalmic compositions comprising an alpha-amylase and optionally other ingredients. The blepharitis is inflammation of eyelids and areas around the eyelids. The blepharitis generally affects both eyes, including areas along the edges of the eyelids. The blepharitis is considered to occur when tiny oil glands near the roots of the eyelashes become clogged, causing stimulation and redness. Several diseases and conditions may be associated with blepharitis.
Owner:INNOKULUS VENTURE CAPITAL CO LTD

Azithromycin-containing ophthalmic agent

PendingJP2025120407AOrganic active ingredientsSenses disorderDiseaseOphthalmic Agents
To provide an ophthalmic agent and an ophthalmic antibacterial agent that contain azithromycin and are administered in specific doses and dosage regimens for specific indications.SOLUTION: The present invention relates to an ophthalmic agent that contains azithromycin and ophthalmologically acceptable additives to prevent or treat one or more of a patient's blepharitis, hordeolum, and lacrimal pouchitis or to prevent the progression of the disease, the ophthalmic agent being applied to the patient twice daily for 2 days and then once daily for 12 days in an appropriate quantity once. The invention also relates to an ophthalmic antibacterial agent.SELECTED DRAWING: None
Owner:SENJU PHARMA CO LTD

Method and device for treating an ocular disorder

ActiveUS12290473B2Eye surgerySwabsMeibomitisRelative motion
A method and apparatus for treating ocular disorders such as blepharitis, meibomitis, and dry eye syndrome. The method includes using an electromechanical device to move a swab relative to the eye to create cyclical movement that impacts debris present at the eyelid margin and effectively removes the debris from the eye to encourage healing and prevent further digression of the health of the eye. The apparatus is an electromechanical device that includes a mechanical drive unit operatively connected to a swab to create a precise relative movement of the swab to the eye to remove debris present therein.
Owner:BLEPHEX LLC

Isoxazoline parasiticide formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC

Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis

ActiveUS12161752B2Organic active ingredientsSenses disorderPosterior blepharitisPharmacy medicine
Disclosed herein are pharmaceutical compositions and methods for the treatment of anterior blepharitis and posterior blepharitis which may be of primary origin and not secondary to other factors such as infections, infestations or rosacea. The composition comprises Ivermectin in the range of about 0.001% to 20% by weight of the total composition. Topical administration of said compositions precisely to the eyelid margin provides therapeutic benefit to patients suffering from anterior blepharitis and posterior blepharitis.
Owner:PADMANABHAN VISHWANATH

Method of treating blepharitis or conjunctivitis

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.
Owner:IVIEW THERAPEUTICS INC

Battery powered heated eye mask

A heated eye mask apparatus for therapeutic treatment of meibomian gland dysfunction, blepharitis, dry eye disease, and related ocular conditions. The apparatus comprises a body portion with adjustable straps and a pair of detachable eye covers releasably secured to the body portion via fastening mechanisms enabling positional adjustment. Each eye cover includes at least one heating element with multiple independently controllable heating zones, allowing targeted thermal therapy to specific periocular anatomical regions. The heating elements are powered by rechargeable batteries integrated within the body portion, providing cordless operation. Flexible tethers connect the eye covers to the body portion, providing mechanical retention and electrical connectivity. A control interface comprising user-actuatable buttons enables independent activation of heating zones. Alternative embodiments may include a steam generation system providing combined heat and moisture therapy. The adjustable configuration accommodates varying facial anatomies and enables customized treatment based on individual therapeutic requirements.
Owner:BLINKJOY INC

Ophthalmic topical cream compositions and methods

An ophthalmic therapeutic treatment composition includes a topical cream containing a crosslinked acrylic acid polymer, an acrylamide / sodium acryloyldimethyl taurate copolymer, and an effective amount of an active pharmaceutical ingredient (API) dispersed in the topical cream. The ophthalmic therapeutic treatment composition and API are formulated for topical application and treatment of various disorders such as dry eye, presbyopia, intraocular pressure and blepharitis.
Owner:GLAUKOS CORP

Topical composition comprising an ophiopogon extract for use in the treatment of eyelids or the contour of the eye

A topical composition comprising, as active ingredient, a mixture of hyaluronic acid, trehalose and an extract of roots of Ophiopogon japonicus, for use as soothing and / or moisturizing agent for the eyelids and / or the contour of the eye in a subject with sensitive skin, in particular with blepharitis.
Owner:LABORATOIRES THEA SAS

New use of zwitterions in ophthalmic topical cream compositions and formulations

An ophthalmic topical cream composition comprising a topical cream comprising at least one zwitterion; and an active pharmaceutical ingredient (API) dispersed in the topical cream. The ophthalmic topical cream compositions and APIs are formulated for topical application and treatment of various conditions, such as dry eye, presbyopia, intraocular pressure, and blepharitis.
Owner:GLAUKOS CORP

Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions

UndeterminedLAP825AOrganic active ingredientsSenses disorderFluticasone propionatePropanoic acid
The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
Owner:NICOX OPHTHALMICS

Treatment for management and prevention of eyelid conditions

Blepharitis, an infection and inflammation of the edge of the eyelids, and meibomian gland dysfunction (MGD), blockage of tiny oil glands at the eye lid margin, are quite common, usually under diagnosed and underappreciated diseases. There are number of causes for blepharitis, including bacterial components such as Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and Corynebacteria sp., seborrhea or microscopic mites (Demodex). More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one of these entities. Another large number of patients remain undiagnosed or in early stages of disease that could be easily treated thus preventing long-term pain and suffering. MGD is in fact the leading cause of dry eye disease, a potentially preventable malady.
Owner:OLKOWSKI JOHN +1

Heterodimer compositions and methods for the treatment of ocular disorders

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and / or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.
Owner:RIPPLE THERAPEUTICS CORP

Eyelid margin inflammation detection device and method, computing device and computer program product

The embodiment of the invention provides an eyelid margin inflammation detection device, an eyelid margin inflammation detection method, computing equipment and a computer program product. The eyelid margin inflammation detection device comprises an image generation module which is used for shooting a to-be-detected eyelid by using a cross polarization light source to generate an eyelid coronal plane image; the signal extraction module is used for performing hemoglobin signal extraction processing on the eyelid coronal plane image to obtain a to-be-detected image; the first detection module is used for dividing an eyelid detection area and an eyelid margin detection area in the to-be-detected image; the first identification module is used for identifying a first hemoglobin abnormal region and a second hemoglobin abnormal region; the first determination module is used for determining a first proportion and a second proportion; and the detection module is used for obtaining a detection result of the to-be-detected eyelid according to the first proportion and the second proportion. According to the technical scheme provided by the embodiment of the invention, the accuracy of blepharitis marginata inflammation detection is improved.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Isoxazoline insect repellant formulations and methods for treating blepharitis

Disclosed herein are methods for treating or preventing ophthalmic and dermatological conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include directly topically administering to the ocular surface of one or more eyes of a patient in need of treatment an effective amount of an isoxazoline insect repellant, a formamidine insect repellant, or other active ingredient formulated as an ophthalmic composition that further includes a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Owner:TARSUS PHARMACEUTICALS INC